Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

IgA nephropathy: a clinical overview.

Bruce A Julian1, Robert J Wyatt, Karel Matousovic

  • 1University of Alabama at Birmingham, Department of Medicine, Birmingham, AL 35294, USA. bjulian@uab.edu

Contributions to Nephrology
|May 15, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum to Loss of GalNAc-T14 links O-glycosylation defects to alterations in B cell homing in IgA nephropathy.

The Journal of clinical investigation·2026
Same author

Inhibition of p65 NF-κB enhances production of galactose-deficient IgA1 through suppression of <i>C1GALT1</i> and SP1 in plasmablast-like cell subpopulations.

bioRxiv : the preprint server for biology·2026
Same author

Proteomic Analysis of Circulating IgA1-Containing Immune Complexes in Patients with IgA Nephropathy.

Kidney international reports·2025
Same author

Kidney injury and colocalization of complement C3, IgA, and IgG in glomerular immune-complex deposits of patients with IgA nephropathy or IgA vasculitis with nephritis.

Kidney international·2025
Same author

IgA Nephropathy in the Elderly.

Kidney international reports·2025
Same author

Loss of GalNAc-T14 links O-glycosylation defects to alterations in B cell homing in IgA nephropathy.

The Journal of clinical investigation·2025
Same journal

Adsorption of Pathogens and Blockade of Sepsis Cascade.

Contributions to nephrology·2023
Same journal

Hemoadsorption: Research Agenda and Potential Future Applications.

Contributions to nephrology·2023
Same journal

Hemoperfusion in Poisoning and Drug Overdose.

Contributions to nephrology·2023
Same journal

Hemoperfusion in Burns.

Contributions to nephrology·2023
Same journal

Sequential Extracorporeal Therapy in Sepsis.

Contributions to nephrology·2023
Same journal

The Use of Adsorption in Extracorporeal Liver Support: The Double Plasma Molecular Adsorption System (DPMAS).

Contributions to nephrology·2023
See all related articles

Recent advancements in IgA nephropathy (IgAN) research highlight familial disease patterns and promising new biomarkers. These developments aid in understanding disease progression and patient stratification.

Area of Science:

  • Nephrology
  • Immunology
  • Genetics

Background:

  • Clinical understanding of IgA nephropathy (IgAN) has evolved since 2004.
  • Familial IgAN cases present with outcomes similar to sporadic forms, yet genetic links remain unclear.
  • Technological progress has spurred interest in biomarkers for IgAN.

Purpose of the Study:

  • To review recent advancements in familial IgA nephropathy.
  • To discuss emerging biomarkers for IgAN diagnosis and monitoring.
  • To explore new prognostic features for IgA nephropathy.

Main Methods:

  • Review of literature and symposium findings post-2004.
  • Analysis of genetic studies on familial IgAN pedigrees.
  • Evaluation of proteomic and biomarker research in IgAN.

Related Experiment Videos

Main Results:

  • Familial IgAN is a significant factor, with similar clinical courses to sporadic IgAN.
  • Potential biomarkers include IgA1 neoepitopes, galactose-deficient IgA, and urinary IgA-IgG complexes.
  • Proteomic analysis reveals urinary polypeptide panels differentiating IgAN patients.

Conclusions:

  • New biomarkers and genetic insights offer improved tools for IgAN classification and management.
  • Further research into biomarkers may enhance disease monitoring and therapeutic response assessment.
  • Understanding familial IgAN contributes to a comprehensive view of the disease.